Siegfried Expands Production Capacity in El Masnou

The latest expansion will significantly increase the site’s sterile eye drop manufacturing capacity in response to growing customer demand. The new capacity will be available for customers beginning in 2027.

This additional expansion complements the company’s ongoing initiative to increase production capacity for sterile eye care ointments, which is expected to be available to customers by 2026. It also includes the acquisition of state-of-the-art equipment compliant with the European Union’s Annex 1 regulations for the manufacture of sterile medicinal products.

Marcel Imwinkelried, CEO, Siegfried, commented, "We see continued strong demand for ophthalmic products and the expansion of our El Masnou site will provide valuable additional capacity for our customers. This expansion enhances our global ophthalmic manufacturing footprint and enables us, together with our ophthalmics site in Irvine, US, to effectively serve Europe and the US.”